Citigroup Maintains Sell on Integra Lifesciences, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 83.9%

Neg 0% Neu 0% Pos 83.9%

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Sell and raises the price target from $9 to $11.